<DOC>
	<DOCNO>NCT00991146</DOCNO>
	<brief_summary>To date approve effective therapy treatment cryopyrin-associated periodic syndrome ( CAPS ) include Familial Cold Autoinflammatory Syndrome ( FCAS ) , Muckle-Wells Syndrome ( MWS ) , Neonatal Onset Multisystem Inflammatory Disease ( NOMID ) Japan . The study ass efficacy safety canakinumab Japanese patient cryopyrin-associated periodic syndrome ( CAPS ) . In previous currently ongoing CAPS study ( CACZ885A2102 , CACZ885D2201 , CACZ885D2304 , CACZ885D2306 ) , observed treatment canakinumab patient CAPS contribute ensure absence relapse , improve sign symptoms prevent secondary disease complication . However , Japanese patient included study . This study allow access Japanese patient new potentially efficacious treatment CAPS patient convenient dose regimen .</brief_summary>
	<brief_title>Efficacy Safety Study Canakinumab Administered 6 Months ( 24 Weeks ) Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . At study entry , patient clinical diagnosis FCAS , MWS NOMID require medication . At time screening , patient either untreated treated medication . 2 . Presence , history least 2 follow symptom : For NOMID patient : Typical NOMID urticarial rash Signs central nervous system ( CNS ) involvement increase intracranial pressure and/or papilledema and/or cerebral spinal fluid pleiocytosis and/or stroke and/or seizure , and/or sensorineural hearing loss Typical arthropatic change Xrays : epiphysal and/or patellar overgrowth With start NOMID symptoms 6 month age For MWS patient : periodic fever headache/migraine arthralgia urticarial skin rash conjunctivitis myalgia sensorineural hearing impairment For FCAS patient : urticarial skin rash fever/chills conjunctivitis joint pain 3 . Patients require oral steroid , NSAIDs and/or diseasemodifying antirheumatic drug ( DMARDs ) enrol stable dose ( oral steroid : &lt; 20 mg/day &lt; = 0.4 mg/kg prednisone prednisone equivalent , whichever applies ) least 4 week prior screen visit . 4 . Able communicate investigator comply requirement study ( child parent assist necessary ) . 1 . Pregnant nursing ( lactate ) woman . 2 . All woman capable become pregnant unless postmenopausal use one method contraception . 3 . Participation study within 30 day 4 . Infection HIV , Hepatitis B C. 5 . Live vaccination within 3 month prior start trial , trial , 3 month follow last dose . 6 . History drug alcohol abuse within 12 month prior dose . 7 . Donation loss 400 mL blood within 8 week prior dose adult . 8 . History significant medical condition , doctor 's opinion would exclude patient participate trial . 9 . History renal transplantation . 10 . Presence additional rheumatic disease significant systemic disease . For example , major chronic infectious/ inflammatory/ immunologic disease ( inflammatory bowel disease , psoriatic arthritis , spondyloarthropathy , systemic lupus erythematosus addition autoinflammatory disease ) . 11 . Presence follow laboratory abnormality : ALT AST great 2 time upper limit normal ( ULN ) , platelet count less 100x109/L . 12 . History recurrent and/or evidence clinically significant active bacterial , fungal , viral infection . 13 . History contact patient suspect tuberculosis symptom ; history complication tuberculosis infection . 14 . Use follow therapy : Etanercept 4 week prior baseline visit ( Day 1 ) thereafter Adalimumab 8 week prior baseline visit ( Day 1 ) thereafter Infliximab 12 week prior baseline visit ( Day 1 ) thereafter Rituximab 26 week prior baseline visit ( Day 1 ) thereafter Tocilizumab 3 week prior baseline visit ( Day 1 ) thereafter Any investigational biologics 8 week prior baseline visit ( Day 1 ) thereafter ( exception anakinra therapysee ) Anakinra therapy baseline visit ( Day 1 ) . Last anakinra injection occur le 6 hour prior canakinumab injection Day 1 Leflunomide 4 week prior baseline visit ( Day 1 ) thereafter . After completion leflunomide treatment cholestiramine dose 8 g 3 time per day 14 day recommend . Thalidomide 4 week prior baseline visit ( Day 1 ) thereafter Cyclosporine 4 week prior baseline visit ( Day 1 ) thereafter i.v . immunoglobulin ( i.v . Ig ) 8 week prior baseline visit ( Day 1 ) thereafter 6Mercaptopurine , azathioprine , cyclophosphamide , chlorambucil 12 week prior baseline visit ( Day 1 ) thereafter Dapsone , mycophenolate mofetil 3 week prior baseline visit ( Day 1 ) thereafter &gt; = 20 mg/day &gt; 0.4 mg/kg , whichever applies , prednisone prednisone equivalent 4 week prior baseline visit ( Day 1 ) thereafter Methyl prednisone pulse therapy 4 week prior baseline visit thereafter 15 . History allergic reaction similar drug . No additional exclusion may apply doctor , order ensure study population representative eligible patient . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CAPS</keyword>
	<keyword>FCAS</keyword>
	<keyword>MWS</keyword>
	<keyword>NOMID</keyword>
	<keyword>cryopyrin-associated periodic syndrome</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome</keyword>
	<keyword>Muckle-Wells Syndrome</keyword>
	<keyword>Neonatal Onset Multisystem Inflammatory Disease</keyword>
	<keyword>canakinumab</keyword>
	<keyword>ACZ885</keyword>
	<keyword>child</keyword>
	<keyword>systemic autoinflammatory disease</keyword>
	<keyword>NALP-3</keyword>
	<keyword>human monoclonal anti-human interleukin-1beta ( IL-1beta ) antibody</keyword>
	<keyword>autosomal dominant</keyword>
	<keyword>familial autoinflammatory syndrome</keyword>
</DOC>